Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anika Therapeutics Inc (NASDAQ:ANIK)

49.64
Delayed Data
As of Dec 09
 +1.50 / +3.12%
Today’s Change
35.07
Today|||52-Week Range
54.96
+30.08%
Year-to-Date
Roche Presents Positive Follicular Lymphoma Data on Gazvya
Dec 06 / Zacks.com - Paid Partner Content
Cytori Scleroderma Study Two-Year Follow-Up Data Published
Nov 30 / Zacks.com - Paid Partner Content
Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
Dec 06 / Zacks.com - Paid Partner Content
PhaseRx Soars on Orphan Drug Status for Rare Liver Disease
Nov 30 / Zacks.com - Paid Partner Content
GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss
Dec 06 / Zacks.com - Paid Partner Content
Foamix Completes Enrolment in Phase III Acne Drug Studies
Nov 30 / Zacks.com - Paid Partner Content
Alexion Presents Data from Ultra-Rare Blood Disorder Study
Dec 05 / Zacks.com - Paid Partner Content
Aimmune Closes Enrolment in Phase III Peanut Allergy Study
Nov 30 / Zacks.com - Paid Partner Content
3 Biotech Stocks to Buy in December
Dec 01 / MotleyFool.com - Paid Partner Content
Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial
Nov 29 / Zacks.com - Paid Partner Content